×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
RDY – dr. reddy's laboratories ltd (US:NYSE)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
RDY
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
3/27
11:47 am
rdy
Bio-Thera and Dr. Reddy's Execute Exclusive Commercialization Agreement for BAT2206, a Proposed Stelara® Biosimilar, and BAT2506, a Proposed Simponi® Biosimilar, for Southeast Asia
Low
Report
Bio-Thera and Dr. Reddy's Execute Exclusive Commercialization Agreement for BAT2206, a Proposed Stelara® Biosimilar, and BAT2506, a Proposed Simponi® Biosimilar, for Southeast Asia
3/24
11:07 am
rdy
Henlius 2024 Annual Results: Steady Revenue Growth with a Net Profit of RMB820.5 million, Up by 50.3% YoY [Yahoo! Finance]
Low
Report
Henlius 2024 Annual Results: Steady Revenue Growth with a Net Profit of RMB820.5 million, Up by 50.3% YoY [Yahoo! Finance]
3/18
10:09 am
rdy
Alvotech and Dr. Reddy's gets FDA nod for Biologic License Application for AVT03 [Seeking Alpha]
Low
Report
Alvotech and Dr. Reddy's gets FDA nod for Biologic License Application for AVT03 [Seeking Alpha]
3/18
08:35 am
rdy
Alvotech and Dr. Reddy’s Announce FDA Acceptance of Biologic License Application for AVT03, a Proposed Biosimilar to Prolia® and Xgeva®
Low
Report
Alvotech and Dr. Reddy’s Announce FDA Acceptance of Biologic License Application for AVT03, a Proposed Biosimilar to Prolia® and Xgeva®
3/13
10:40 am
rdy
Dr. Reddy's Issues a Nationwide Recall of Levetiracetam in 0.75% Sodium Chloride Injection 1,000 mg/100 mL, in the U.S., due to Mislabeling of Infusion Bag
Neutral
Report
Dr. Reddy's Issues a Nationwide Recall of Levetiracetam in 0.75% Sodium Chloride Injection 1,000 mg/100 mL, in the U.S., due to Mislabeling of Infusion Bag
3/7
08:29 am
rdy
Will Trump Drug Tariffs Help Or Hurt The U.S.? [Forbes]
Low
Report
Will Trump Drug Tariffs Help Or Hurt The U.S.? [Forbes]
3/4
07:41 am
rdy
Pediatrica Health Group Acquires the Rainbow Pediatric Center Group of Practices and Sets a Course for Change [Yahoo! Finance]
Low
Report
Pediatrica Health Group Acquires the Rainbow Pediatric Center Group of Practices and Sets a Course for Change [Yahoo! Finance]
3/1
07:07 pm
rdy
Is Dr. Reddy's Laboratories Limited (RDY) the Best Weight Loss Drug Stock to Buy According to Analysts? [Yahoo! Finance]
Low
Report
Is Dr. Reddy's Laboratories Limited (RDY) the Best Weight Loss Drug Stock to Buy According to Analysts? [Yahoo! Finance]
Date
Time
Symbol
Company Name
Action
%Chg
1/24/2025
10:35 pm
rdy
dr. reddy's laboratories ltd
BEAT
Report
-3.1%
dr. reddy's laboratories ltd
1/24/2025
10:20 pm
rdy
dr. reddy's laboratories ltd
BEAT
Report
-3.1%
dr. reddy's laboratories ltd
1/24/2025
10:05 pm
rdy
dr. reddy's laboratories ltd
BEAT
Report
-3.1%
dr. reddy's laboratories ltd
1/24/2025
09:51 pm
rdy
dr. reddy's laboratories ltd
BEAT
Report
-3.1%
dr. reddy's laboratories ltd
Date
Time
Action
From
To
Firm
Impact
%Chg
Date
Time
Symbol
Headline
Impact
3/24
06:24 am
rdy
Form 6-K DR REDDYS LABORATORIES For: Mar 22
Low
Report
Form 6-K DR REDDYS LABORATORIES For: Mar 22
3/21
02:41 pm
rdy
Form 6-K DR REDDYS LABORATORIES For: Mar 21
Low
Report
Form 6-K DR REDDYS LABORATORIES For: Mar 21
3/13
01:36 pm
rdy
Form 6-K DR REDDYS LABORATORIES For: Mar 13
Neutral
Report
Form 6-K DR REDDYS LABORATORIES For: Mar 13
3/12
07:53 am
rdy
Form 6-K DR REDDYS LABORATORIES For: Mar 12
Low
Report
Form 6-K DR REDDYS LABORATORIES For: Mar 12
3/7
11:02 am
rdy
Form 6-K DR REDDYS LABORATORIES For: Mar 07
Low
Report
Form 6-K DR REDDYS LABORATORIES For: Mar 07
3/6
07:33 am
rdy
Form 6-K DR REDDYS LABORATORIES For: Mar 06
Low
Report
Form 6-K DR REDDYS LABORATORIES For: Mar 06
3/3
06:17 am
rdy
Form 6-K DR REDDYS LABORATORIES For: Feb 28
Low
Report
Form 6-K DR REDDYS LABORATORIES For: Feb 28
2/25
07:43 am
rdy
Form 6-K DR REDDYS LABORATORIES For: Feb 25
Low
Report
Form 6-K DR REDDYS LABORATORIES For: Feb 25
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
3/13
Dr.Reddy's Laboratories Ltd (NYSE: RDY) was upgraded by analysts at ValuEngine from a "sell" rating to a "hold" rating.
6.2%
1/27 Form 6-K DR REDDYS LABORATORIES For: Jan 27 5.3%
4/9 Form SC 13G/A DR REDDYS LABORATORIES Filed by: BlackRock Inc. 4.8%
3/20 Dr. Reddy's launches pyrimethamine tablets in U.S. [Seeking Alpha] 3.9%
3/17 Dr. Reddy's Laboratories announces the launch of Ziprasidone Mesylate for Injection in the U.S. Market 3.0%
10/23 Dr. Reddy’s Confirms Its Voluntary Nationwide Recall of All Ranitidine Products in the U.S. Market 2.8%
7/29 Dr. Reddy's Laboratories Limited 2020 Q1 - Results - Earnings Call Slides [Seeking Alpha] 2.8%
9/11 Hazmat situation reported at Dr. Reddy's New York facility [Seeking Alpha] 2.8%
5/20 Q4/2019 3/31/2019 EPS 26.160 ZacksConsensus N/A ActVsEst N/A - N/A 2.7%
9/9 Form SC 13G DR REDDYS LABORATORIES Filed by: COMMONWEALTH BANK OF AUSTRALIA 2.4%
1/27 Form 6-K DR REDDYS LABORATORIES For: Jan 27 5.3%
4/9 Form SC 13G/A DR REDDYS LABORATORIES Filed by: BlackRock Inc. 4.8%
3/20 Dr. Reddy's launches pyrimethamine tablets in U.S. [Seeking Alpha] 3.9%
3/17 Dr. Reddy's Laboratories announces the launch of Ziprasidone Mesylate for Injection in the U.S. Market 3.0%
10/23 Dr. Reddy’s Confirms Its Voluntary Nationwide Recall of All Ranitidine Products in the U.S. Market 2.8%
7/29 Dr. Reddy's Laboratories Limited 2020 Q1 - Results - Earnings Call Slides [Seeking Alpha] 2.8%
9/11 Hazmat situation reported at Dr. Reddy's New York facility [Seeking Alpha] 2.8%
5/20 Q4/2019 3/31/2019 EPS 26.160 ZacksConsensus N/A ActVsEst N/A - N/A 2.7%
9/9 Form SC 13G DR REDDYS LABORATORIES Filed by: COMMONWEALTH BANK OF AUSTRALIA 2.4%
TOP News Decliners
3/12
Form 6-K DR REDDYS LABORATORIES For: Mar 12
-6.6%
5/17 Q4/2019 3/31/2019 EPS 26.160 ZacksConsensus N/A ActVsEst N/A - N/A -6.0%
3/16 Form 6-K DR REDDYS LABORATORIES For: Mar 14 -4.6%
7/29 Dr. Reddy’s Q1 FY20 Financial Results -3.3%
7/29 Q1/2020 6/30/2019 EPS 39.910 ZacksConsensus N/A ActVsEst N/A - N/A -2.9%
7/23 Form 6-K DR REDDYS LABORATORIES For: Jul 23 -2.5%
2/27 Dr. Reddy's Laboratories Announces the First Generic Launch of Naproxen and Esomeprazole Magnesium Delayed-Release Tablets in the U.S. Market -2.3%
5/17 Q4/2019 3/31/2019 EPS 26.160 ZacksConsensus N/A ActVsEst N/A - N/A -1.9%
10/23 Dr. Reddy's is recalling some products used to treat heartburn [CNN] -1.8%
11/22 Dr. Reddy's Laboratories announces launch of Doxercalciferol Injection in the U.S. Market -1.7%
5/17 Q4/2019 3/31/2019 EPS 26.160 ZacksConsensus N/A ActVsEst N/A - N/A -6.0%
3/16 Form 6-K DR REDDYS LABORATORIES For: Mar 14 -4.6%
7/29 Dr. Reddy’s Q1 FY20 Financial Results -3.3%
7/29 Q1/2020 6/30/2019 EPS 39.910 ZacksConsensus N/A ActVsEst N/A - N/A -2.9%
7/23 Form 6-K DR REDDYS LABORATORIES For: Jul 23 -2.5%
2/27 Dr. Reddy's Laboratories Announces the First Generic Launch of Naproxen and Esomeprazole Magnesium Delayed-Release Tablets in the U.S. Market -2.3%
5/17 Q4/2019 3/31/2019 EPS 26.160 ZacksConsensus N/A ActVsEst N/A - N/A -1.9%
10/23 Dr. Reddy's is recalling some products used to treat heartburn [CNN] -1.8%
11/22 Dr. Reddy's Laboratories announces launch of Doxercalciferol Injection in the U.S. Market -1.7%
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: